 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...6364656667686970717273...7475» |
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (clinicaltrials.gov) - Aug 21, 2014
P2, N=40, Not yet recruiting, Sponsor: Greater Houston Retina Research
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: CARE-ROP: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (clinicaltrials.gov) - Aug 21, 2014
P2, N=40, Recruiting, Sponsor: University Hospital Freiburg
Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=75, Completed, Sponsor: National Eye Institute (NEI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial primary completion date, Monotherapy: Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) (clinicaltrials.gov) - Aug 15, 2014
P1/2, N=40, Active, not recruiting, Sponsor: David M. Brown, M.D.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Jul 2017
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: CHIC-3: Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion (clinicaltrials.gov) - Aug 15, 2014
P4, N=45, Completed, Sponsor: Centre Hospitalier Intercommunal Creteil
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Jul 2017 Recruiting --> Completed
- ||||| Fovista (pegpleranib) / Roche, Astellas
New P2a trial, Combination therapy: Phase 2A Open Label Safety Study of Fovista (clinicaltrials.gov) - Aug 12, 2014
P2a, N=100, Recruiting, Sponsor: Ophthotech Corporation
- Lucentis (ranibizumab) / Roche, Novartis
Clinical: Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=240, Not yet recruiting, Sponsor: PolyPhotonix Medical
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial withdrawal: Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing (clinicaltrials.gov) - Jul 30, 2014
P2, N=0, Withdrawn, Sponsor: Maturi, Raj K., M.D., P.C.
Recruiting --> Completed N=20 --> 0 | Not yet recruiting --> Withdrawn
- |||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment open: A Study of Abicipar Pegol in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jul 21, 2014
P2, N=140, Recruiting, Sponsor: Allergan
N=20 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- ||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=324, Completed, Sponsor: Allergan
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Rayoqta (abicipar pegol) / Molecular Partners
New P2 trial: A Study of Abicipar Pegol in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jul 12, 2014
P2, N=140, Not yet recruiting, Sponsor: Allergan
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: OLIMPIC: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (clinicaltrials.gov) - Jul 10, 2014
P3, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Jan 2014 --> Jun 2014
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial initiation date: OLIMPIC: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (clinicaltrials.gov) - Jul 10, 2014
P3, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Jun 2014
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: COMRADE-C: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Jul 10, 2014
P3, N=243, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Jun 2014 Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=25, Completed, Sponsor: University of Luebeck
Active, not recruiting --> Completed N=20 --> 25
- | Rayoqta (abicipar pegol) / Molecular Partners
New P2 trial: A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jul 8, 2014
P2, N=25, Recruiting, Sponsor: Allergan
- | Rayoqta (abicipar pegol) / Molecular Partners
New P2 trial: A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jul 8, 2014
P2, N=25, Not yet recruiting, Sponsor: Allergan
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=25, Completed, Sponsor: University of Luebeck
N=20 --> 25 Active, not recruiting --> Completed | N=20 --> 25
- |||| Rayoqta (abicipar pegol) / Molecular Partners
Trial completion: Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jul 3, 2014
P2, N=271, Completed, Sponsor: Allergan
Active, not recruiting --> Completed | N=20 --> 25 Active, not recruiting --> Completed
- PAN-90806 / PanOptica
Trial primary completion date: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Jul 1, 2014
P1, N=50, Recruiting, Sponsor: PanOptica, Inc.
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Nov 2014
- PAN-90806 / PanOptica
Enrollment change, Trial primary completion date: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Jul 1, 2014
P1, N=50, Recruiting, Sponsor: PanOptica, Inc.
Trial primary completion date: Aug 2014 --> Nov 2014 N=30 --> 50 | Trial primary completion date: Aug 2014 --> Nov 2014
- Lucentis (ranibizumab) / Roche, Novartis
Clinical: VEGF and PEDF in Patients With Myopic Choroidal Neovascularization (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=40, Completed, Sponsor: Università degli Studi di Brescia
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2) (clinicaltrials.gov) - Jun 18, 2014
P2, N=72, Completed, Sponsor: Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
N=30 --> 50 | Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Sep 2011 --> Jan 2014
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2) (clinicaltrials.gov) - Jun 18, 2014
P2, N=72, Completed, Sponsor: Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
Trial primary completion date: Sep 2011 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jan 2014
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date, Surgery: OCTOPUS: Use of Ranibizumab With Mitomycin C During Trabeculectomy (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jan 2014 Trial primary completion date: Sep 2013 --> Sep 2014
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Surgery: OCTOPUS: Use of Ranibizumab With Mitomycin C During Trabeculectomy (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Sep 2013 --> Sep 2014 Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: UNRAVEL: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jun 12, 2014
P4, N=204, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Jul 2015
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: UNRAVEL: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jun 12, 2014
P4, N=204, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2015 --> Jul 2015 Initiation date: Jan 2014 --> Apr 2014
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: SAFARI: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (clinicaltrials.gov) - Jun 12, 2014
P4, N=162, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: UNRAVEL: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jun 12, 2014
P4, N=204, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Clinical: QUATRO: Ranibizumab Treatment for Age-Related Macular Degeneretion (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=100, Recruiting, Sponsor: Kyushu University
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: CONSTELLATION: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Jun 4, 2014
P3, N=155, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Feb 2017
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: SALT: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (clinicaltrials.gov) - Jun 4, 2014
P4, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2016 --> Feb 2017 Trial primary completion date: Oct 2015 --> Jul 2016
- |||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial primary completion date: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Jun 4, 2014
P3, N=475, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Jul 2016 Trial primary completion date: Jan 2015 --> Jan 2016
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date, Combination therapy: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (clinicaltrials.gov) - Jun 4, 2014
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Apr 2015 --> Jan 2017
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: CONSTELLATION: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Jun 4, 2014
P3, N=155, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2015 --> Jan 2017 Initiation date: Jan 2014 --> May 2014
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, Enrollment change: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jun 4, 2014
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2014 --> May 2014 N=350 --> 500
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: RIVAL: A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (clinicaltrials.gov) - Jun 4, 2014
P4, N=278, Recruiting, Sponsor: Novartis Pharmaceuticals
N=350 --> 500 Not yet recruiting --> Recruiting
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: CONSTELLATION: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Jun 4, 2014
P3, N=155, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: DRAGON: Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (clinicaltrials.gov) - Jun 4, 2014
P4, N=333, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO (clinicaltrials.gov) - Jun 4, 2014
P4, N=175, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: ARI2: Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Jun 3, 2014
P3, N=90, Recruiting, Sponsor: Centre Hospitalier Intercommunal Creteil
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=300, Recruiting, Sponsor: NJ Retina
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - May 27, 2014
P3, N=670, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Jul 2016
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: TWEYES: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (clinicaltrials.gov) - May 27, 2014
P4, N=5000, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2016 --> Jul 2016 Initiation date: Dec 2013 --> Mar 2014
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - May 27, 2014
P3, N=670, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2013 --> Mar 2014 Initiation date: Mar 2012 --> Jun 2013
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion date: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - May 27, 2014
P3, N=670, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2012 --> Jun 2013 Trial completion date: Apr 2016 --> Jul 2016
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: TWEYES: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (clinicaltrials.gov) - May 27, 2014
P4, N=5000, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration (clinicaltrials.gov) - May 21, 2014
P1/2, N=100, Completed, Sponsor: Arshad Khanani
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> May 2014
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration (clinicaltrials.gov) - May 21, 2014
P1/2, N=100, Completed, Sponsor: Arshad Khanani
Trial primary completion date: Sep 2014 --> May 2014 Trial completion date: Oct 2014 --> May 2014